J. Buesa

4.7k total citations
61 papers, 3.6k citations indexed

About

J. Buesa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, J. Buesa has authored 61 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in J. Buesa's work include Sarcoma Diagnosis and Treatment (34 papers), Vascular Tumors and Angiosarcomas (19 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Buesa is often cited by papers focused on Sarcoma Diagnosis and Treatment (34 papers), Vascular Tumors and Angiosarcomas (19 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Buesa collaborates with scholars based in Spain, United Kingdom and Netherlands. J. Buesa's co-authors include Armando Santoro, Jaap Verweij, Henning T. Mouridsen, T Türsz, M. van Glabbeke, R. Somers, A.T. van Oosterom, J. Wolter Oosterhuis, V. Bramwell and D. Crowther and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

J. Buesa

61 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Buesa Spain 26 2.9k 2.1k 769 687 567 61 3.6k
Arthur P. Staddon United States 29 2.4k 0.8× 1.4k 0.7× 482 0.6× 318 0.5× 426 0.8× 67 3.5k
Alessandro Comandone Italy 25 2.3k 0.8× 1.4k 0.7× 539 0.7× 621 0.9× 475 0.8× 103 3.0k
T Türsz France 14 1.5k 0.5× 1.2k 0.6× 542 0.7× 325 0.5× 351 0.6× 38 1.9k
Steven Attia United States 23 1.4k 0.5× 1.0k 0.5× 377 0.5× 321 0.5× 327 0.6× 140 2.1k
M. A. Burgess United States 19 980 0.3× 960 0.5× 315 0.4× 256 0.4× 191 0.3× 41 1.8k
Bernadette Liegl‐Atzwanger Austria 25 1.3k 0.4× 863 0.4× 176 0.2× 528 0.8× 191 0.3× 109 2.2k
Agnès Neuville France 27 1.2k 0.4× 704 0.3× 309 0.4× 307 0.4× 436 0.8× 56 2.0k
Javier Martínez‐Trufero Spain 20 1.1k 0.4× 976 0.5× 204 0.3× 533 0.8× 207 0.4× 124 2.0k
Roberta Sanfilippo Italy 27 2.1k 0.7× 1.4k 0.7× 932 1.2× 225 0.3× 337 0.6× 98 2.5k
Gunnar Sæter Norway 33 2.4k 0.8× 1.3k 0.6× 507 0.7× 646 0.9× 399 0.7× 77 3.4k

Countries citing papers authored by J. Buesa

Since Specialization
Citations

This map shows the geographic impact of J. Buesa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Buesa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Buesa more than expected).

Fields of papers citing papers by J. Buesa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Buesa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Buesa. The network helps show where J. Buesa may publish in the future.

Co-authorship network of co-authors of J. Buesa

This figure shows the co-authorship network connecting the top 25 collaborators of J. Buesa. A scholar is included among the top collaborators of J. Buesa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Buesa. J. Buesa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muro, Xavier García del, Antonio López–Pousa, Joan Maurel, et al.. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. 29(18). 2528–2533. 197 indexed citations
2.
Esteban, Emilio, N. Villanueva, Yolanda Fernández, et al.. (2007). Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Investigational New Drugs. 26(1). 67–74. 16 indexed citations
3.
López–Pousa, Antonio, Javier Martín‐Broto, Joaquín Montalar, et al.. (2006). Phase II Trial of Doxorubicin Plus Escalated High‐Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma. 2006(1). 26986–26986. 4 indexed citations
4.
5.
Sierra, Marta, et al.. (2006). Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection. Journal of Chromatography B. 840(1). 44–49. 29 indexed citations
6.
7.
8.
9.
López–Pousa, Antonio, J. Buesa, Javier García del Muro, et al.. (2004). Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS). Journal of Clinical Oncology. 22(14_suppl). 9033–9033. 2 indexed citations
10.
Gortzak, E., Alberto Azzarelli, J. Buesa, et al.. (2001). A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. European Journal of Cancer. 37(9). 1096–1103. 275 indexed citations
11.
Verweij, Jaap, W. Ruka, J. Buesa, et al.. (2000). Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.. International Journal of Clinical Oncology. 18. 2081–2086. 30 indexed citations
12.
13.
Dombernowsky, P, H.T. Mouridsen, D. Crowther, et al.. (1998). High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. British Journal of Cancer. 78(12). 1634–1639. 78 indexed citations
14.
15.
Buesa, J., Antonio López–Pousa, Javier Martín‐Broto, et al.. (1998). Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology. 9(8). 871–876. 50 indexed citations
16.
Geel, A.N. van, Ugo Pastorino, K. W. Jauch, et al.. (1996). Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 77(4). 675–682. 200 indexed citations
17.
18.
Verweij, Jaap, A.T. van Oosterom, R. Somers, et al.. (1992). Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. Annals of Oncology. 3. S75–S80. 18 indexed citations
19.
Blackledge, G., A. van Oosterom, Henning T. Mouridsen, et al.. (1990). Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. European Journal of Cancer and Clinical Oncology. 26(2). 139–141. 24 indexed citations
20.
Blackledge, G., A. van Oosterom, Henning T. Mouridsen, et al.. (1989). The place of chemotherapy in the management of soft tissue sarcoma: Experiences of the EORTC soft tissue and bone sarcoma group. Clinical Oncology. 1(2). 106–109. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arthur P. Staddon Breakdown of academic impact, for papers by Alessandro Comandone Breakdown of academic impact, for papers by T Türsz Breakdown of academic impact, for papers by Steven Attia Breakdown of academic impact, for papers by M. A. Burgess Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger Breakdown of academic impact, for papers by Agnès Neuville Breakdown of academic impact, for papers by Javier Martínez‐Trufero Breakdown of academic impact, for papers by Roberta Sanfilippo Breakdown of academic impact, for papers by Gunnar Sæter
Rankless by CCL
2026